ESTRO 2025 - Abstract Book

S638

Clinical - Breast

ESTRO 2025

For phase two, the differences appear, but the resulting field parameters are still acceptable. The final field positions vary from initial, because QMP is allowed to change them to create an adequate plan. Still, the AI suggested solutions qualify as within the limits of "minor adjustments".

Conclusion: he proposed solution offers time saving at the treatment planning process, providing adequate and standardized starting point for further, personalized planning, through multicriterial optimization process, which represents the basis of ongoing prospective study. Based on these starting plans a new tool that would create full 3DCRT treatment plans can be developed.